Program
modzatinib
Also written as “Modzatinib” and “ATI-2138”.
Its studies are mostly in Lichen Planus · Dermatitis, Atopic, led by Aclaris Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aclaris Therapeutics | 21 open or running | phase 2since Sep 3, 2024 | Sep 3, 2024 | Mar 2029phase 2 · NCT07935590 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Sep 3, 2024First study: phase 2 study in Dermatitis, AtopicFirst studyNCT06585202 · 14 enrolled · United States
- Jul 10, 2025Named modzatinibINNProposed as its International Nonproprietary Name in WHO's List 133 · before, ATI-2138
- Nov 9, 2026Phase 2 study in Lichen PlanusNCT07935590 · 102 planned · United States
Ahead
- Mar 2029Primary completion: phase 2 study in Lichen PlanusNCT07935590
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07935590Lichen Planus · United States | 2 | Recruiting | Mar 2029 | 102 |
| NCT06585202Dermatitis, Atopic · United States | 2 | Completed | Mar 13, 2025 | 14 |
How it is read
Names in the registry
- “Modzatinib”, 1 entry
- “ATI-2138”, 1 entry
Conditions, from the studies’ own filings
- Lichen Planus, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.